AI picks who gets a second chance at targeted breast cancer therapy
NCT ID NCT07227233
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether an artificial intelligence model can identify patients with advanced HR+ HER2- breast cancer whose tumors might still respond to a second CDK4/6 inhibitor after the first stopped working. About 105 participants will either receive the AI-recommended drug combination or standard care chosen by their doctor. The goal is to see if the AI-guided approach delays tumor growth and is safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of California, San Diego
RECRUITINGLa Jolla, California, 92093, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?